Build status - In Progress

A Study of REGN5678 (anti-PSMAxCD28) with Cemiplimab (anti-PD-1) in Patients with Metastatic Prostate Cancer

Recruiting
18 years - 99 years
Male
Phase N/A
1 Location

Brief description of study

This study involves research and is conducted to determine the safety, tolerability (how 6 your body reacts to the drug) and effectiveness of a study drug called REGN5678 which 7 will be given alone first and then be given in combination with cemiplimab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Cancer
  • Age: 18 years - 99 years
  • Gender: Male

Males, aged 18 or older, diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma.

Updated on 04 Aug 2024. Study ID: 849839

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center